Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Trial Profile

24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms FREEDOMS-II
  • Sponsors Novartis
  • Most Recent Events

    • 12 Oct 2018 Results of a post hoc analysis of FREEDOMS and FREEDOMS II trials and their extensions assessing the predictive value of MRI parameters for physical and cognitive outcomes in MS, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 14 Mar 2018 Results of a pooled analysis from FREEDOMS and FREEDOM II studies (n=2064) published in the Neurology.
    • 28 Oct 2017 Results of pooled analysis of FREEDOMS, FREEDOMS II and LONGTERMS trials,presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top